The Life Sciences Capital Markets team represented the underwriters in connection with Krystal Biotech’s approximately $125 million follow-on offering of its common stock. The offering consisted of 2,275,000 shares of Krystal’s common stock, which were sold to investors at a price of $55.00 per share. The underwriters have a 30-day option to purchase up to an additional 341,250 shares of common stock. Cowen and Company, LLC and Evercore Group L.L.C. acted as joint book-running managers.
Krystal is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases.
For additional details on the offering, please read Krystal’s press release.